Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.53 |
| ▸ | NNMT | P40261 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20097198 | 0.91 | DOT1L (0.54) | DOT1LNNMTADORA1TRDMT1ATM | |
| SCHEMBL20096729 | 0.91 | NNMT (0.52) | DOT1LNNMTADORA1ATMCARM1 | |
| SCHEMBL20096727 | 0.90 | DOT1L (0.54) | DOT1LNNMTADORA1ATM | |
| SCHEMBL20097185 | 0.88 | DOT1L (0.58) | DOT1LNNMTADORA1ATM | |
| SCHEMBL20097027 | 0.87 | DOT1L (0.58) | DOT1LNNMTADORA1 | |
| SCHEMBL20096728 | 0.85 | DOT1L (0.56) | DOT1LNNMTADORA1 | |
| SCHEMBL21311197 | 0.83 | DOT1L (0.35) | DOT1LNNMT | |
| SCHEMBL20097197 | 0.82 | NNMT (0.53) | DOT1LNNMTADORA1ATMCARM1 | |
| SCHEMBL20097183 | 0.81 | DOT1L (0.54) | DOT1LNNMTADORA1ATM | |
| SCHEMBL20096733 | 0.81 | DOT1L (0.54) | DOT1LNNMTADORA1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
| WO-2018075947-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | DOT1L 2274/4885NNMT 865/4885ADORA1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.